logo
episode-header-image
Jun 2024
31 m

Cost vs. Quality: The Debate on Generic ...

THE ECONOMIC TIMES
About this episode

Government-run Jan Aushadhi Kendras and chains like Generic Aadhaar offer medicines at a fraction of market prices, but pharma giants warn of quality risks. So, why is the All India Drug Action Network (AIDAN) advocating for the promotion of generic medicines despite quality concerns? How do pharmacy chains like Generic Aadhaar ensure the quality and affordability of their generic drugs? In the latest episode of The Morning Brief podcast, host Kiran Somvanshi delves into the heated debate over low-cost generic medicines with  Dr. Gopal Dabade from the Drug Action Forum, Arjun Deshpande of Generic Aadhaar, and ET's pharma expert Vikas Dandekar to explore the pros and cons of this pivotal policy move. Tune in!


Check out other interesting episodes like: Polls on My Pod: The Adversaries in Punjab and Bengal, Polls on My Pod: Kashmir Finally Speaks Up!, Polls on My Pod: Ground Check on Delhi, Haryana Elections, Polls on My Pod: The Jal, Jangal, Zameen Struggle, Polls on My Pod: The Rae Bareli Fight & Gujarat’s Rajput Agitation, and more!

You can follow our host Kiran Somvanshi on her social media: Twitter & Linkedin

Catch the latest episode of ‘The Morning Brief’ on ET Play, The Economic Times Online, Spotify, Apple Podcasts, JioSaavn,  Amazon Music and Google Podcasts.

See omnystudio.com/listener for privacy information.

Up next
Aug 22
South Capital: TN’s Playbook of Distrubuted Growth
In this episode of South Capital, the focus is on Tamil Nadu, India's manufacturing powerhouse and one of its most industrialized states. Known as the “Detroit of Asia” for its auto sector and the “Manchester of the South” for its textiles, Tamil Nadu plays a pivotal role in Indi ... Show More
27m 7s
Aug 21
Rare Earths to Rx: Explaining the India-China Reset
For months, India has felt the squeeze of China’s export chokehold on rare earth magnets vital for EVs, fertilizers key to food security, and raw materials that keep pharma running. Automakers faced stalled assembly lines, farmers braced for higher costs, and drugmakers feared su ... Show More
29m 4s
Aug 19
India’s Setting New Rules for the Digital Space, but Why?
Another week, another rulebook for India’s digital economy this time, a competition code. The Digital Competition Bill (DCB) would flip enforcement from ex-post litigation to ex-ante guardrails for “systemically significant” platforms, banning self-preferencing, data misuse again ... Show More
20m 39s
Recommended Episodes
Sep 2023
Money Talks: The price of cheaper medicines
One of the many aims of President Joe Biden’s signature legislation, the Inflation Reduction Act, is to cut the cost of drugs prescribed by Medicare, a government health insurance programme for Americans 65 and over. But the policy could have some side-effects for patients far be ... Show More
44m 53s
Sep 2023
Money Talks: The price of cheaper medicines
One of the many aims of President Joe Biden’s signature legislation, the Inflation Reduction Act, is to cut the cost of drugs prescribed by Medicare, a government health insurance programme for Americans 65 and over. But the policy could have some side-effects for patients far be ... Show More
44m 53s
Jun 2021
The Struggles of India’s Vaccine Giant
When the coronavirus hit, the Serum Institute of India, the world’s largest vaccine maker, seemed uniquely positioned to help. It struck a deal with AstraZeneca, promising a billion vaccine doses to low- and middle-income nations. Earlier this year, a ban instituted by Prime Mini ... Show More
28m 1s
Oct 2021
Sick Money (Pt 1): Exposing the drug companies' price gouging tactics
In the first of two episodes this week, we're taking a deep dive into the pharmaceutical industry. How much does the medication you take actually cost? What if a company came along and bought the rights to a particular drug and started charging double, triple, or even 10,000 time ... Show More
29m 31s
Oct 2021
Sick Money (Pt 2): How Big Pharma made a killing from the pandemic
The second of two episodes this week, taking a deep dive into the pharmaceutical industry.Big drug companies have won plaudits for their work producing Covid vaccines within a year of the start of the pandemic. How much money are they making from them? And why are vaccines for ot ... Show More
24m 39s
Jul 2023
28: Paul Nurse: The power of genetics, battling politicians, and the fight against cancer
How close are we to finding a cure for cancer? What did the government do wrong - in scientific terms - during the pandemic? Do Labour or the Tories have a proper plan to harness the power of British science? On today’s episode of Leading, Alastair and Rory are joined by Nobel Pr ... Show More
1h 4m
Aug 2023
After 30 Years, Here's Biden's Plan To Lower Drug Costs: Negotiate
The government announced the first ten drugs that are the subject of price negotiations between the U.S. government and private companies. For decades, the government has been prohibited from negotiating the price it pays through Medicare for medication — until the rule was relax ... Show More
12m 23s
May 2024
The world after Ozempic
Ozempic and other new weight loss drugs are being touted as potential miracle cures for diabetes and obesity. Journalist Johann Hari experimented with the drug and dropped 40 pounds. In his new book, Magic Pill, Hari discusses his experience with Ozempic and speaks to many of the ... Show More
50m 53s
Sep 2023
Ep. 1222 - Big Pharma Once Again Makes Billions Off Of A Drug That Doesn't Work
Today on the Matt Walsh Show, it's been revealed that some very popular cold medicines that many people have been using for years are effectively useless. They don't work at all, reportedly. This is just the latest example of Big Pharma making billions on a product that doesn't d ... Show More
1h 7m